93 percent of advanced leukemia patients in remission after immunotherapy

Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers. This study is the first CAR T-cell trial to infuse patients with an even mixture of two types of T cells (helper and killer cells, which work together to kill cancer).